A Phase I Study of HMPL-523, a Selective Oral Anti-Spleen Tyrosine Kinase Inhibitor, in Patients with Relapsed or Refractory LymphomaN. Fowler, W. Jurczak,R. Cordoba Mascunano,P. Abrisqueta Costa,P. Strati,C. Yang,M. Kania,J. Kauh,A. J. M. FerreriAnnals of oncology（2019）引用 0|浏览38暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
